Trends in first-line TKI prescribing preferences (PPrefs) among U.S.-based hematology-oncology physicians (HOPs) for patients with chronic phase chronic myelogenous leukemia (CP-CML).
Neil P. Shah
Research Funding - ARIAD; Bristol-Myers Squibb
Arden Buettner
No relevant relationships to disclose
Maria Lankford
No relevant relationships to disclose
Joanne Willey
No relevant relationships to disclose
Doug B. Neely
No relevant relationships to disclose
Mark R. Green
No relevant relationships to disclose